RT Journal Article
SR Electronic
T1 Rapid homogeneous assay for detecting antibodies against SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.01.20224113
DO 10.1101/2020.11.01.20224113
A1 Rusanen, Juuso
A1 Kareinen, Lauri
A1 Levanov, Lev
A1 Mero, Sointu
A1 Pakkanen, Sari H.
A1 Kantele, Anu
A1 Amanat, Fatima
A1 Krammer, Florian
A1 Hedman, Klaus
A1 Vapalahti, Olli
A1 Hepojoki, Jussi
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.01.20224113.abstract
AB Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Antibody tests enable detection of individuals past the initial phase of infection and will help to examine possible vaccine responses. The major targets of human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (S) and nucleocapsid protein (N). We have developed a rapid homogenous approach for antibody detection termed LFRET (protein L-based time-resolved Förster resonance energy transfer immunoassay). In LFRET, fluorophore-labeled protein L and antigen are brought to close proximity by antigen-specific patient immunoglobulins of any isotype, resulting in TR-FRET signal generation.We set up LFRET assays for antibodies against S and N and evaluated their diagnostic performance using a panel of 77 serum/plasma samples from 44 individuals with COVID-19 and 52 negative controls. Moreover, using a previously described S construct and a novel N construct, we set up enzyme linked immunosorbent assays (ELISAs) for antibodies against SARS-CoV-2 S and N. We then compared the LFRET assays with these enzyme immunoassays and with a SARS-CoV-2 microneutralization test (MNT).We found the LFRET assays to parallel ELISAs in sensitivity (90-95% vs. 90-100%) and specificity (100% vs. 94-100%). In identifying individuals with or without a detectable neutralizing antibody response, LFRET outperformed ELISA in specificity (91-96% vs. 82-87%), while demonstrating an equal sensitivity (98%).In conclusion, this study demonstrates the applicability of LFRET, a 10-minute ‘mix and read’ assay, to detection of SARS-CoV-2 antibodies.Competing Interest StatementK.H., J.H. and O.V are among inventors in a patent WO2015128548 describing the LFRET assay utilized in the manuscript.Funding StatementThe authors received funding for this work from the following institutions: the Sigrid Jusélius Foundation, the Magnus Ehrnrooth Foundation, Finnish Society of Sciences and Letters, the Research Funds of University of Helsinki and Helsinki University Hospital, Finska Läkaresällskapet, the Finnish Medical Foundation, Academy of Finland (#1308613, #1336490, #336439 and #335527), Juho Vainio Foundation, Private donors through UH, Jane and Aatos Erkko Foundation, EU Horizon 2020 programme VEO (grant No. 874735) and Helsinki University Hospital Funds (TYH 2018322).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data and samples were collected under research permit HUS/211/2020 and ethics committee approval HUS/853/2020 (Helsinki University Hospital, Finland).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data are included in the article and the supplementary information.